Oric Pharmaceuticals had its Relative Strength (RS) Rating upgraded from 90 to 93 Wednesday.
How To Use Stock Charts To Stay Profitable And Protected
IBD's proprietary rating measures share price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
History reveals that the best stocks typically have an RS Rating north of 80 as they launch their largest price moves.
Oric Pharmaceuticals is not currently offering a proper buying opportunity. See if the stock goes on to build a base that could spark a new run.
The company reported 0% earnings growth last quarter. Revenue rose 0%.
Oric Pharmaceuticals earns the No. 125 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
